Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB2 | P05107 | 13/20 | 0.79 |
| ▸ | ICAM1 | P05362 | 13/20 | 0.79 |
| ▸ | ITGAL | P20701 | 13/20 | 0.79 |
| ▸ | POLB | P06746 | 3/20 | 0.69 |
| ▸ | MAPT | P10636 | 2/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.69 |
| ▸ | HPGD | P15428 | 1/20 | 0.69 |
| ▸ | TP53 | P04637 | 1/20 | 0.69 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.66 |
| ▸ | ACE | P12821 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16834384 | 0.88 | ITGB2 (0.74) | ITGB2ICAM1ITGALPOLBMAPT | |
| SCHEMBL30081478 | 0.88 | ITGB2 (0.74) | ITGB2ICAM1ITGALPOLBMAPT | |
| SCHEMBL11869919 | 0.86 | ITGB2 (0.80) | ITGB2ICAM1ITGALPOLBMAPT | |
| SCHEMBL12063160 | 0.86 | ITGB2 (0.71) | ITGB2ICAM1ITGALPOLBMAPT | |
| SCHEMBL1358036 | 0.86 | ITGB2 (0.80) | ITGB2ICAM1ITGALPOLBMAPT | |
| SCHEMBL11869604 | 0.86 | ITGB2 (0.80) | ITGB2ICAM1ITGALPOLBMAPT | |
| SCHEMBL11868630 | 0.86 | ITGB2 (0.80) | ITGB2ICAM1ITGALPOLBMAPT | |
| SCHEMBL1358031 | 0.86 | ITGB2 (0.80) | ITGB2ICAM1ITGALPOLBMAPT | |
| SCHEMBL15145360 | 0.86 | ITGB2 (0.74) | ITGB2ICAM1ITGALPOLBMAPT | |
| SCHEMBL11949519 | 0.86 | ITGB2 (0.85) | ITGB2ICAM1ITGALPOLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10188641-B2 | Compositions and methods for treatment | SARCODE BIOSCIENCE INC. (US) | 2019-01-29 | — | — | US | disclosed |
| US-20140161872-A1 | COMPOSITIONS AND METHODS FOR TREATMENT | SARCODE BIOSCIENCE INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140161872-A1 | COMPOSITIONS AND METHODS FOR TREATMENT | SARCODE BIOSCIENCE INC. (US) | 2014-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10188641-B2 | Compositions and methods for treatment | ICAM1, VCAM1, ITGAL | ITGB2 8/4885ICAM1 1/4885ITGAL 3/4885 |
| US-20140161872-A1 | COMPOSITIONS AND METHODS FOR TREATMENT | ICAM1, VCAM1, ITGAL | ITGB2 8/4885ICAM1 1/4885ITGAL 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.